ArticleThe Journal of biological chemistry2017
Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis.
Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Truncated FOS impairs osteogenic differentiation and induces prostaglandin and NFκB signalling in an in vitro cell-of-origin model for osteoid osteoma and osteoblastoma.The Journal of pathology · 2026Article
- FOS gene fusions in osteosarcoma raise the hypothesis of malignant transformation of osteoblastoma.Virchows Archiv : an international journal of pathology · 2026Article
- Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing ofFrontiers in immunology · 2025Article
- FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis.Frontiers in cardiovascular medicine · 2025Article
- Recurrent cementoblastoma with multifocal growth and cellular atypia: a case report.Diagnostic pathology · 2024Article
- Genomic Profiling of the Craniofacial Ossifying Fibroma by Next-Generation Sequencing.Head and neck pathology · 2023Article
- Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma.The Journal of pathology · 2023Article
- The genetics of vascular tumours: an update.Histopathology · 2022Review
- Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.Scientific reports · 2021Article
- Article
- Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Epithelioid hemangioma of bone harboring FOS and FOSB gene rearrangements: A clinicopathologic and molecular study.Genes, chromosomes & cancer · 2021Article
- Identification of a Novel Gene Correlated With Vascular Smooth Muscle Cells Proliferation and Migration in Chronic Thromboembolic Pulmonary Hypertension.Frontiers in physiology · 2021Article
- Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express theCell reports. Medicine · 2020Article
- Loss of NF2 defines a genetic subgroup of non-FOS-rearranged osteoblastoma.The journal of pathology. Clinical research · 2020Article
- TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness.Oncogene · 2020Article
- Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.Virchows Archiv : an international journal of pathology · 2020Article
- Article
- What's new in bone forming tumours of the skeleton?Virchows Archiv : an international journal of pathology · 2020Review
- Hydroxychloroquine enhances the antitumor effects of BC001 in gastric cancer.International journal of oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid hemangioma is a locally aggressive vascular neoplasm, found in bones and soft tissue, whose cause is currently unknown, but may involve oncogene activation. FOS is one of the earliest viral oncogenes to be characterized, and normal cellular FOS forms part of the activator protein 1 (AP-1) transcription factor complex, which plays a pivotal role in cell growth, differentiation, and survival as well as the DNA damage response. Despite this, a causal link between aberrant FOS function and naturally occurring tumors has not yet been established. Here, we describe a thorough molecular and biochemical analysis of a mutant FOS protein we identified in these vascular tumors. The mutant protein lacks a highly conserved helix consisting of the C-terminal four amino acids of FOS, which we show is indispensable for fast, ubiquitin-independent FOS degradation via the 20S proteasome. Our work reveals that FOS stimulates endothelial sprouting and that perturbation of normal FOS degradation could account for the abnormal vessel growth typical of epithelioid hemangioma. To the best of our knowledge, this is the first functional characterization of mutant FOS proteins found in tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.